Parameters | Positive control group (n = 5) | Group received ranitidine (n = 5) | Group received nizatidine (n = 5) | p |
---|---|---|---|---|
Serum FSH (ng/mL) | ||||
• 2 week after | 0.75 ± 0.07 | 1.38 ± 0.14a | 1.8 ± 0.07a,b | < 0.0001* |
• 3 weeks after | 0.76 ± 0.07 | 2.83 ± 0.31a | 2.08 ± 0.13a,b | < 0.0001* |
• 4 weeks after | 0.73 ± 0.07 | 3.18 ± 0.22a | 3.5 ± 0.27a | < 0.0001* |
Serum LH (pg/mL) | ||||
• 2 week after | 0.73 ± 0.06 | 1.11 ± 0.12a | 1.34 ± 0.05a,b | < 0.0001* |
• 3 weeks after | 0.7 ± 0.06 | 1.71 ± 0.2a | 1.38 ± 0.07a | < 0.0001* |
• 4 weeks after | 0.71 ± 0.06 | 2.12 ± 0.23a | 2.34 ± 0.13a | < 0.0001* |
Serum prolactin (ng/mL) | ||||
• 2 week after | 2.68 ± 0.12 | 2.88 ± 0.26 | 3.3 ± 0.25a,b | < 0.0001* |
• 3 weeks after | 2.53 ± 0.12 | 3.62 ± 0.33a | 2.9 ± 0.2a,b | < 0.0001* |
• 4 weeks after | 2.34 ± 0.12 | 3.74 ± 0.22a | 3.5 ± 0.18a | < 0.0001* |
Serum total testosterone (ng/mL) | ||||
• 2 week after | 2.45 ± 0.11 | 1.32 ± 0.1a | 1.25 ± 0.19a | < 0.0001* |
• 3 weeks after | 2.25 ± 0.11 | 1.06 ± 0.13a | 1.28 ± 0.23a | < 0.0001* |
• 4 weeks after | 2.15 ± 0.11 | 0.76 ± 0.05a | 0.92 ± 0.05a,b | < 0.0001* |
Serum-free testosterone (pg/mL) | ||||
• 2 week after | 11.54 ± 0.71 | 9.08 ± 0.32a | 9.06 ± 0.22a | < 0.0001* |
• 3 weeks after | 11.34 ± 0.71 | 8.86 ± 0.44a | 8.84 ± 0.38a | < 0.0001* |
• 4 weeks after | 10.44 ± 0.71 | 6.84 ± 0.51a | 7.42 ± 0.26a | < 0.0001* |